[Form 3] ALX Oncology Holdings Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

ALX Oncology Holdings Inc. (ALXO) filed an initial Form 3 on behalf of Daniel J. Curran, reporting his relationship to the issuer as a Director. The filing states the event date as 08/12/2025 and includes a signed submission dated 08/13/2025 executed by Shelly Pinto under power of attorney. The document explicitly states no securities are beneficially owned by the reporting person.

Positive

• Director relationship disclosed for Daniel J. Curran, providing transparency on his role
• Form 3 filed promptly with event date 08/12/2025 and submission dated 08/13/2025

Negative

• No securities beneficially owned by the reporting person as of the filing date, indicating no disclosed equity alignment
• Initial ownership statement shows zero holdings, which may be noteworthy for investors assessing insider alignment

Insights

Corporate Governance Expert

TL;DR: Director appointment recorded with no ownership disclosed.

The filing documents that Daniel J. Curran is a Director of ALX Oncology Holdings Inc. and submits an initial ownership statement.

Crucially, the Form 3 declares no securities beneficially owned, which is an explicit disclosure of zero equity position at the reporting date and is relevant for ownership alignment and insider trading monitoring.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Curran Daniel J.

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/12/2025

3. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Shelly Pinto, by power of attorney	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the ALXO Form 3 filed for Daniel J. Curran disclose?

The Form 3 discloses that Daniel J. Curran is a Director of ALX Oncology (ALXO) and that he beneficially owns no securities as of the event date 08/12/2025.

When was the initial statement of beneficial ownership dated and filed?

The event date on the Form 3 is 08/12/2025 and the filing is signed/submitted on 08/13/2025 by Shelly Pinto under power of attorney.

Who signed the Form 3 for Daniel J. Curran?

The Form 3 is signed as /s/ Shelly Pinto, by power of attorney with the signature date 08/13/2025.

Does the filing show any derivative or non-derivative securities for the reporting person?

No. The filing explicitly states no securities are beneficially owned and includes no entries in Table I or Table II.

What is the reporting relationship of Daniel J. Curran to ALX Oncology?

The Form 3 marks the reporting person as a Director of ALX Oncology Holdings Inc.